Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2011-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Nilotinib Versus Imatinib in GIST Patients

NCT00785785

Gastrointestinal Stromal Tumor (GIST)

COMPLETED PHASE3

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

NCT01289028

Gastrointestinal Stromal Tumors

COMPLETED PHASE3

Efficacy and Safety of Nilotinib (AMN107) Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib

NCT00471328

Gastrointestinal Stromal Tumors

COMPLETED PHASE3

Nilotinib in Advanced Gastrointestinal Stromal Tumors (GIST)

NCT00782834

Gastrointestinal Stromal Tumors

TERMINATED PHASE2

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

NCT00633295

Gastrointestinal Stromal Tumors (GIST)

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastrointestinal Stromal Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nilotinib

Group Type EXPERIMENTAL

Nilotinib

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nilotinib

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed diagnosis of GIST that is unresectable and/or metastatic
* Radiological confirmation of disease progression or intolerance to imatinib therapy at a any dose
* At least one measurable site of disease on CT scan at Visit-2
* WHO Performance Status of 0, 1 or 2 at Visit-2
* Patients must have normal organ, electrolyte, and marrow function at Visit-1 and Visit-2

Exclusion Criteria

* Prior treatment with nilotinib or any other tyrosine kinase inhibitors except imatinib.
* Treatment with any cytotoxic and/or investigational cytotoxic drug ≤ 4 weeks
* Prior or concomitant malignancies other than GIST
* Impaired cardiac function at Visit-1 or 2
* Patients with severe and/or uncontrolled concurrent medical disease
* Use of therapeutic coumarin derivatives
* Use of any medications that prolong the QT interval
* Use of CYP3A4 inhibitors
* Patients who have undergone major surgery ≤ 2 weeks prior to Visit-1 or who have not recovered from side effects of such surgery
* Patients who have received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation \< 2 weeks prior to Visit-1 or who have not recovered from side effects of such therapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No